Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
<!-- Name:DistributionId Value:8802734 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
GD2SADA
Y-mAbs’ Announces Clearance of IND for GD2-SADA
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development…